Anhui Bulaatu Pharmaceutical Technology

Anhui Bolatu Pharmaceutical Technology is a clinical-stage biotechnology company focused on the development of innovative therapies for respiratory, inflammatory, and viral diseases. Founded by a team of experienced scientists from global pharmaceutical leaders like Gilead and GSK, the company specializes in high-potency glucocorticoids and anti-viral agents. Its lead candidate, PA9159, is a novel glucocorticoid being evaluated in clinical trials for indications including allergic rhinitis and bronchial asthma. Additionally, the company is advancing a pipeline of anti-hepatitis B virus (HBV) drugs that aim to provide superior efficacy over existing treatments. Bolatu operates out of the Suzhou Economic and Technological Development Zone in Anhui, China.